Metabolic biomarker of pancreatic cancer

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K07266
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Kobe University
• Principal Investigator: KOBAYASHI Takashi 神戸大学, 医学研究科, 助教 (90709669)
• Co-Investigator(Kenkyū-buntansha): 西海 信 神戸大学, 医学研究科, 医学研究員 (20514706)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: 代謝物バイオマーカー

Outline of Final Research Achievements

Although early detection of pancreatic cancer is difficult, it is known that detection and tracking of intraductal papillary mucinous neoplasm (IPMN) can contribute to early detection. In this study, we explored metabolite biomarkers for detection of IPMN and pancreatic cancer. Metabolites in the blood of 44 cases of pancreatic cancer, 15 cases of high-risk IPMN, and 46 cases of healthy subjects were analyzed by GC/MS, and a diagnostic formula combining methionine, arabinose, histidine, and lysine with BMI, ALP, and HbA1c was developed. The sensitivity of this diagnostic formula for pancreatic cancer/high-risk IPMN was 92% and the specificity was 90%.

Free Research Field

メタボロミクス

Academic Significance and Societal Importance of the Research Achievements

これまでCTやMRIなど大規模な検査が必要であったIPMNを血液バイオマーカーによって検出することができれば、より効率的に膵癌高リスク保因者を拾い上げることができ、膵癌の嘔気発見に寄与できる可能性がある。また疾病によってヒトの代謝環境が特異的に変化していることを示唆しており、疾患診断や治療効果予測、予後予測など幅広い応用が期待できる。